arrow
E

Enrico Derenzini

ieo european institute of oncology irccs
H指数:33
被引数:4,186

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BCR::ABL1-positive chronic myeloid leukaemia in a scenario of a remote diagnosis of JAK2-V617F-mutated polycythemia vera: a single patient experience with imatinib and ruxolitinib combination therapy

BCR::ABL1阳性慢性髓系白血病,在JAK2-V617F突变真性红细胞增多症远程诊断场景下的单例病例:伊马替尼与芦可替尼联合治疗经验

2025-10-250
OA
Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation

添加抗胸腺细胞球蛋白对异基因移植后环磷酰胺的影响(与外周血相比):与单独使用异基因移植后环磷酰胺相比的影响:代表欧洲血液与骨髓移植学会细胞治疗与免疫生物学工作组进行的一项回顾性研究

2025-08-070
OAAI
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study

异基因造血干细胞移植治疗复发/难治性B细胞非霍奇金淋巴瘤的长期预后:一项意大利多中心合作研究

2025-06-010
PREAI
Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma

BCL-2介导的rRNA合成下调可诱导弥漫性大B细胞淋巴瘤产生化疗耐药性

2025-05-010
OAAI
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort

基于维奈克拉茨方案的八旬慢性淋巴细胞白血病患者:疗效、安全性及与BTKi的比较(多中心队列研究)

2025-04-240
OA
PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

PRIMAVERA:一项模块化I/II期研究,旨在评估AZD3470(一种蛋白质精氨酸甲基转移酶5 [PRMT5] 抑制剂)在复发/难治性血液恶性肿瘤受试者中的安全性、耐受性和有效性

BLOOD
IF23.1
2024-11-050
PRE
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2024-11-011
PRE
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
2023-10-013
OAAI
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study
2023-06-292
OA
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
2023-02-213
OAAI